$12.24
0.16% yesterday
Nasdaq, Sep 27, 10:10 pm CET
ISIN
US86150R1077
Symbol
STOK

Stoke Therapeutics Inc Stock price

$12.24
-1.63 11.75% 1M
-1.93 13.62% 6M
+6.98 132.70% YTD
+8.34 213.85% 1Y
-14.82 54.77% 3Y
-8.29 40.38% 5Y
-5.76 32.00% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
-0.02 0.16%
ISIN
US86150R1077
Symbol
STOK

Key metrics

Market capitalization $645.46m
Enterprise Value $369.23m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 24.36
P/S ratio (TTM) P/S ratio 42.58
P/B ratio (TTM) P/B ratio 2.64
Revenue growth (TTM) Revenue growth 71.36%
Revenue (TTM) Revenue $15.16m
EBIT (operating result TTM) EBIT $-114.53m
Free Cash Flow (TTM) Free Cash Flow $-80.62m
Cash position $282.06m
EPS (TTM) EPS $-2.19
P/E forward negative
P/S forward 43.41
EV/Sales forward 24.83
Short interest 26.32%
Show more

Is Stoke Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Stoke Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Stoke Therapeutics Inc forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Stoke Therapeutics Inc forecast:

Buy
89%
Hold
11%

Financial data from Stoke Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
15 15
71% 71%
100%
- Direct Costs 4.64 4.64
6% 6%
31%
11 11
136% 136%
69%
- Selling and Administrative Expenses 37 37
12% 12%
246%
- Research and Development Expense 83 83
5% 5%
549%
-110 -110
2% 2%
-725%
- Depreciation and Amortization 4.64 4.64
6% 6%
31%
EBIT (Operating Income) EBIT -115 -115
2% 2%
-756%
Net Profit -104 -104
1% 1%
-683%

In millions USD.

Don't miss a Thing! We will send you all news about Stoke Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Stoke Therapeutics Inc Stock News

Positive
Seeking Alpha
21 days ago
STOK's zorevunersen shows strong efficacy in reducing seizures but has safety concerns, particularly elevated CSF protein levels, needing further monitoring. Dravet Syndrome market potential is significant, with 35,000 patients in key regions and existing treatments costing up to $96,000 annually. STOK has a solid cash runway for 7-8 quarters, with a Phase 3 trial expected to start soon, aiming...
Neutral
Business Wire
25 days ago
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced that management will present at the following upcoming investor conferences: H.C. Wainwright 26th Annual Global Investment Conference Date: Tuesday, September 10, 2024 Time: 12:00 p.m. ET...
Neutral
Business Wire
about one month ago
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced that, effective on August 15, 2024, the company granted stock options to purchase an aggregate of 48,400 shares of common stock to three new employees, as a material inducement to their e...
More Stoke Therapeutics Inc News

Company Profile

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues, including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.

Head office United States
CEO Edward Kaye
Employees 110
Founded 2014
Website www.stoketherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today